Keep pulling the thread on Kian.
Nucleus's product, Nucleus Embryo, is a genetic optimization software that analyzes raw DNA files from embryos to provide reports on risks and traits.
Nucleus claims to be the first company to have partnered with a couple to optimize their embryos specifically on the basis of intelligence.
Kian predicts that the genetics industry will consolidate, with disparate segments like genealogy (23andMe), clinical testing (Natera, Myriad Genetics), and IVF testing all converging into a single application based on whole genome sequencing.
Kian predicts that genome technology will ultimately be as powerful and consequential as artificial intelligence.
Kian believes the convergence of cheaper and more powerful genome sequencing, analysis, and editing technologies will create a trillion-dollar business opportunity.
One in 50 babies born today are conceived via in vitro fertilization (IVF).
The cost of whole genome sequencing has fallen from approximately $1 billion to a few hundred dollars.
An estimated 2.8 million people in the United States have a genetic disease.
According to a study cited by Kian, over 50% of people find genetic optimization for a trait like IQ to be acceptable.
A study cited by Kian found that 40% of people would genetically optimize their children if it could help them get into a better college.
The Nucleus Embryo software provides analysis on an embryo's genetic predisposition for cancers, heart conditions, mental health conditions like schizophrenia, and physical traits such as IQ, height, eye color, and hair color.
Nucleus has formed a strategic partnership with Genomic Prediction, a company specializing in genome-wide testing for embryos.